Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells

International Journal of Pharmaceutics

Volumn 241, Issue 1, 2002, Pages 57-64

  Wasan, Ellen K ^a   Waterhouse, Dawn ^b   Sivak, Olena ^a   Bally, Marcel B ^b   Klasa, Richard J ^b   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Antisense therapy; Bcl 2; Human complement proteins; Human melanoma cells; Lipoplexes; Lipoproteins; Phosphorothioate oligodeoxynucleotides; Plasma proteins

Indexed keywords

DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DIOLEYLDIMETHYLAMMONIUM CHLORIDE; LIPOSOME; OBLIMERSEN; UNCLASSIFIED DRUG;

ARTICLE; CELL TRANSPORT; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DIALYSIS; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; INCUBATION TIME; MELANOMA CELL; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; TEMPERATURE; ULTRACENTRIFUGATION;

BLOOD PROTEINS; COMPLEMENT ACTIVATION; GENE THERAPY; GENES, BCL-2; HUMANS; LIPIDS; LIPOPROTEINS; MELANOMA; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN BINDING; TUMOR CELLS, CULTURED;

EID: 0037043081     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(02)00131-X     Document Type: Article

References (17)

1. Effect of aspirin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats
2. In vivo pharmacokinetics of oligonucleotides
3. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides
4. 3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid
5. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression
6. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model
7. Delivery systems for antisense oligonucleotides
8. Effects if ISIS 2302, a phosphorothioate oligonucleotide, on in vitro and in vivo coagulation parameters
9. Activation of the alternate pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action
10. Chemosensitisation of malignant melanoma by BCL2 antisense therapy
11. Fate of cationic liposomes and their complex with oligonucleotide in vivo
12. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer
13. Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer
14. Pharmacokinetics of oligonucleotides: A review of current knowledge and issues for the future
15. A comparison of step-gradient and sequential density ultracentrifugation and the use of lipoprotein deficient plasma controls in determining the plasma lipoprotein distribution of lipid-associated nystatin and cyclosporine
16. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
17. Cationic lipids enhanced cellular uptake and activity of Bcl-2 antisense oligodeoxynucleotide G3139 in HL-60 cells